Assertio Holdings, Inc.
Assertio Holdings, Inc. is a U.S.-based pharmaceutical company built around a small portfolio of marketed, approved products in oncology, neurology, and pain management. Its commercial model relies on a mix of direct sales force activity and omni-channel promotion, with ROLVEDON as the core branded product and Sympazan and other products supported through digital and remote promotion. The company has grown largely through acquisitions and licensing of established products rather than internal drug discovery. In 2025, it also simplified the portfolio by ceasing commercialization of Otrexup and divesting Assertio Therapeutics, leaving a more focused commercial platform centered on marketed specialty pharmaceuticals.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueProducts used to reduce complications from cancer treatment, centered on ROLVEDON.
Neurology-focused branded therapy promoted through direct and omni-channel channels, mainly Sympazan.
Established pain and inflammation products including INDOCIN, SPRIX, and CAMBIA.
Royalty revenue from licensed product rights, including CAMBIA in Canada.
Products
Reported · share of revenue- ROLVEDON57.5 %
- INDOCIN Products15.9 %
- Sympazan9.6 %
- Product Other9.0 %
- SPRIX Nasal Spray6.7 %
- Royalty1.4 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Assertio sells primarily to healthcare providers and institutions that prescribe or administer specialty pharmaceuticals, rather than to end consumers. ROLVEDON is positioned for hospitals and community oncology clinics, where oncologists and infusion centers need supportive care to reduce febrile neutropenia risk during chemotherapy. Sympazan and the pain portfolio are aimed at prescribers in neurology and pain management, with access influenced by payor coverage and patient-provider support services. The company also relies on national and regional payors because reimbursement and formulary access are critical to adoption of branded specialty drugs. In Canada, CAMBIA generates royalty income through a licensee that markets the product locally.
They buy or administer ROLVEDON because it supports chemotherapy patients at risk of infection and febrile neutropenia.
They prescribe Sympazan for patients needing a branded neurology therapy and respond to omni-channel promotion and access support.
They prescribe INDOCIN, SPRIX, and CAMBIA for pain and inflammation indications where branded access and familiarity matter.
They influence whether patients can access Assertio products through formulary placement, coverage, and reimbursement terms.
They commercialize CAMBIA in Canada and generate royalty revenue for Assertio.
Strategy
Assertio’s strategy is to concentrate on a smaller set of differentiated, approved products and use commercial execution to extend their life cycles. The company is emphasizing ROLVEDON as its lead asset and is looking for additional opportunities in hospitals and community oncology clinics, including evidence generation such as same-day dosing trial results. It is also using an omni-channel model for Sympazan and other products to improve reach while controlling selling costs. Portfolio pruning, including the end of Otrexup commercialization and the divestiture of Assertio Therapeutics, suggests a focus on simplifying operations and allocating capital to products with better commercial prospects. Management also highlights supply-chain and inventory discipline because product sales, working capital timing, and inventory purchases can materially affect cash needs.
ROLVEDON is the company’s core branded growth driver and the main source of commercial focus.
Digital and remote promotion can extend reach for smaller specialty products without a large field footprint.
Removing lower-priority assets can reduce operating complexity and focus capital on higher-value products.
Geography
Assertio is headquartered in the United States and its commercial activity is primarily U.S.-centric, reflecting the domestic market for its branded specialty pharmaceuticals. The company’s products are marketed through U.S. sales force and omni-channel channels, while reimbursement and access decisions by U.S. payors are a major determinant of demand. Canada is relevant through the CAMBIA licensing arrangement, which produces royalty revenue rather than direct product sales. The 2025 divestiture of Assertio Therapeutics also reduced complexity in the operating footprint, leaving a more focused commercial base. No authoritative country revenue table was provided in the excerpts, so the geographic profile is based on disclosed operations and licensing relationships rather than a formal revenue split.
Risks
Assertio faces concentration risk because a relatively small portfolio means that changes in ROLVEDON, INDOCIN, or Sympazan demand can materially affect results. The company also depends on payor access, so reimbursement pressure or formulary restrictions can slow adoption even when products are clinically differentiated. Generic competition and product lifecycle erosion are important industry risks for established pharmaceuticals, especially in pain management. The reports also highlight elevated legal and activist-related costs, including litigation tied to former portfolio assets and investor disputes, which can distract management and increase SG&A expense. In addition, inventory timing, supply costs, and macroeconomic conditions can create volatility in cash flow and operating performance.
- Litigation and activist-related costsImpact: HighLikelihood: High
The company disclosed ongoing litigation and activist campaigns that have generated significant legal and other fees.
Exposure: SG&A and management attention
- Dependence on ROLVEDON commercial performanceImpact: HighLikelihood: Medium
The company’s growth and commercial focus are centered on a single lead product, so any slowdown in uptake would have an outsized impact.
Exposure: Oncology supportive care portfolio
- Payor access and reimbursement restrictionsImpact: HighLikelihood: Medium
Specialty pharmaceuticals often require favorable coverage and formulary placement to achieve broad patient access.
Exposure: U.S. commercial portfolio
- Inventory and supply chain volatilityImpact: MediumLikelihood: Medium
Product sales depend on timely inventory purchases, manufacturing, and distribution, which can create cost and cash flow swings.
Exposure: Commercial operations
- Generic and competitive erosionImpact: MediumLikelihood: Low
Legacy pain products are vulnerable to lower-priced alternatives and market share loss over time.
Exposure
Accounting
Judgemental itemsPharmaceutical net sales depend on estimates for rebates, chargebacks, returns, and discounts, which can change reported revenue materially.
Impact: Net sales and gross-to-net deductions
Acquired inventory and product volume changes affect cost of sales through step-up amortization and write-downs.
Impact: Gross margin and quarterly cost volatility
Management concluded it is not more likely than not that deferred tax assets will be realized, so tax expense may not reflect statutory rates.
Impact: Income tax expense and effective tax rate
Acquired product rights and other long-lived assets require impairment testing if product performance weakens.
Impact: Potential non-cash charges to earnings
Similar listed companies
Publicly listed companies with a comparable business focus.
Lexicon Pharmaceuticals, Inc
LXRX · Pharmaceutical Preparations
Lexicon Pharmaceuticals is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines.
Minerva Neurosciences, Inc.
NERV · Pharmaceutical Preparations
AIM ImmunoTech Inc.
AIM · Biological Products, (No Diagnostic Substances)
Amylyx Pharmaceuticals, Inc.
AMLX · Pharmaceutical Preparations
Silexion Therapeutics Corp
SLXN · Biological Products, (No Diagnostic Substances)
Silexion Therapeutics Corp is a U.S.-listed holding company whose operations are conducted primarily through its subsidiary Silexion, a clinical-stage…
Lantheus Holdings, Inc.
LNTH · In Vitro & In Vivo Diagnostic Substances
Last updated: 24/09/2026